Rennova Health, Inc. (NASDAQ:RNVA) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07.Submission of Matters to a Vote of Security Holders.
On December 22, 2016, Rennova Health, Inc. (the Company) held its
Annual Meeting of Stockholders (the Annual Meeting) to approve
the following proposals: (i) to elect five directors, each to
hold office until the Company’s next Annual Meeting of
Stockholders or until their successors are duly elected and
qualified; (ii) to ratify the appointment of Green Company, CPAs
as our independent registered public accounting firm for the
fiscal year ending December 31, 2016; (iii) to approve an
amendment to our Certificate of Incorporation to effect a reverse
split of all of the outstanding shares of our common stock, par
value $0.01 per share, at a specific ratio within a range from
1-for-10 to 1-for-30, and to grant authorization to the Board of
Directors to determine, in its discretion, the specific ratio and
timing of the reverse split any time before December 31, 2017,
subject to the Board of Directors discretion to abandon such
amendment; (iv) to approve an advisory (non-binding) resolution
on the Companys executive compensation; and (v) to transact such
other business as may properly come before the Annual Meeting and
any adjournment or postponement thereof.
All proposals were approved by the Companys stockholders. Set
forth below are the final voting results for each proposal
submitted to a vote of the stockholders at the Annual Meeting.
There were 25,858,428 broker non-votes recorded with respect to
each proposal. For more information on the following proposals,
see the Companys definitive proxy statement filed with the
Securities and Exchange Commission on December 5, 2016.
Proposal 1: Elect five directors, each to hold office until the
Company’s next Annual Meeting of Stockholders or until their
successors are duly elected and qualified:
| For | Withhold | |
| Seamus Lagan | 26,714,067 | 3,215,561 |
| Dr. Paul Billings | 26,769,847 | 3,159,781 |
| Christopher Diamantis | 26,733,500 | 3,196,128 |
| Michael Goldberg | 26,750,203 | 3,179,425 |
| Robert Lee | 26,784,758 | 3,144,870 |
Benjamin Frank had been a nominee to continue serving as a
director but, as previously disclosed, he passed away on December
18, 2016, prior to the Annual Meeting.
Proposal 2: Ratify the appointment of Green Company, CPAs as our
independent registered public accounting firm for the fiscal year
ending December 31, 2016:
| For | 27,665,119 |
| Against | 155,812 |
| Abstain | 2,108,697 |
Proposal 3: Approve an amendment to our Certificate of
Incorporation to effect a reverse stock split of all of the
outstanding shares of our common stock, par value $0.01 per
share, at a specific ratio within a range from 1-for-10 to
1-for-30, and to grant authorization to the Board of Directors to
determine, in its discretion, the specific ratio and timing of
the reverse split any time before December 31, 2017, subject to
the Board of Directors discretion to abandon such amendment.
| For | 28,530,797 |
| Against | 1,393,468 |
| Abstain | 5,363 |
Proposal 4: Approve an advisory (non-binding) resolution on the
Companys executive compensation.
| For | 26,229,240 |
| Against | 1,171,362 |
| Abstain | 2,002,026 |
Proposal 5: Transact such other business as may properly come
before the Annual Meeting and any adjournment or postponement
thereof.
| For | 26,766,637 |
| Against | 1,120,885 |
| Abstain | 2,042,106 |
About Rennova Health, Inc. (NASDAQ:RNVA)
Rennova Health, Inc. (Rennova), formerly CollabRx, Inc., is a provider of diagnostics and supportive software solutions to healthcare providers. The Company operates in three segments: clinical laboratory operations, supportive software solutions, and decision support and informatics operations. The Company is a healthcare enterprise that delivers products and services, including laboratory diagnostics, healthcare technology solutions, and revenue cycle management and intends to provide financial services, to medical providers. Rennova’s principal line of business is clinical laboratory blood and urine testing services. It is also engaged in the provision of urine drug toxicology testing to physicians, clinics and rehabilitation facilities in the United States. Its clinical laboratories include Biohealth Medical Laboratory, Inc.; Alethea Laboratories, Inc.; International Technologies, LLC; EPIC Reference Labs, Inc., and Epinex Diagnostics Laboratories, Inc. Rennova Health, Inc. (NASDAQ:RNVA) Recent Trading Information
Rennova Health, Inc. (NASDAQ:RNVA) closed its last trading session down -0.0009 at 0.0870 with 5,241,198 shares trading hands.